Israeli Cannabis Technology Company BYND Cannasoft Enterprises Files US Provisional Patent Application and Full Scale PCT Application for Its EZ-G Device
January 17 2023 - 7:30AM
BYND Cannasoft Enterprises
Inc.
(Nasdaq:
BCAN)
(CSE:
BYND)
("
BYND
Cannasoft" or the "
Company") announced
today that in addition to the US Provisional Patent Application
with serial number 63/297,009 that was filed on January 6, 2022,
covering the monitoring and controlling aspects of its EZ-G device,
the company filed a full-scale PCT application on January 5, 2023,
under serial number PCT/IL2023/050016. The PCT application is based
on BYND Cannasoft’s prototype of the EZ-G device that is currently
under development and its operational aspects as a learning adult
device. The PCT application further claims priority from the US
Provisional application and covers an adult device with a structure
and one or more moving and vibrating elements.
In addition to potentially treating annoying phenomena in the
female reproductive system, the EZ-G device includes technological
advancements as a sex toy with a more realistic experience. The
EZ-G device prototype uses sensors like a pressure sensor,
temperature sensor, conductivity sensor, and heart rate sensor to
determine what specifically enhances the users' pleasure. The EZ-G
device uses artificial intelligence (AI) to transmit and receive
data from the device's sensors on conditions of the user's sexual
organs, such as moisture levels and pressure variations due to
muscle contraction. The EZ-G prototype includes a Bluetooth
component for controlling the adult device via an app installed on
a smartphone or other portable device to collect user information
about preferences and generate custom programs. The data collected
from the sensors is uploaded to the secured cloud, where it is
combined with other antonymic user's preferences, including the
actual duration of operation of the adult device, lubrication
level, and the ideal vibration level. This information optimizes
the operation of the device to satisfy the user sexually. The EZ-G
device uses the collected secured data to learn the users'
responses and improve its operation to bring the user sexual
satisfaction.
Wearable tech has seen tremendous growth in recent years. When
most people think of wearables, they think of fitness trackers and
smartwatches, but there is also an emerging trend in wearable sex
toys. The excitement of a sex toy and the thrill of clandestine
public stimulation have contributed to this trend. Cannasoft
intends to take advantage of the growth in the sextech market,
which is expected to reach $62.32 by 2030. According to Forbes,
companies are working to innovate products that have an intelligent
response for sexual activity to take advantage of this expected
growth.
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said, "The
EZ-G device has evolved to provide treatment relief from sexual and
mental problems, including the ability to have intercourse as it
relates to anxiety and physical pain. The device is capable of
enhancing sexual pleasure and reducing sexual pain by dispensing a
low concentrations of CBD oil lubricant in a controlled manner. It
could be configured to use disposable capsules that include the CBD
lubricant, which could be dispensed in accordance with data
collected by the sensors. The sale of the disposable capsules
containing the CBD lubricant would provide BYND Cannasoft with a
revenue model much like the razor and the razor blade."
About BYND Cannasoft Enterprises
Inc.
BYND Cannasoft Enterprises is an Israeli-based integrated
software and cannabis company. BYND Cannasoft owns and markets
"Benefit CRM," a proprietary customer relationship management (CRM)
software product enabling small and medium‐sized businesses to
optimize their day‐to‐day business activities such as sales
management, personnel management, marketing, call center
activities, and asset management. Building on our 20 years of
experience in CRM software, BYND Cannasoft is developing an
innovative new CRM platform to serve the needs of the medical
cannabis industry by making it a more organized, accessible, and
price-transparent market. The Cannabis CRM System will include a
Job Management (BENEFIT) and a module system (CANNASOFT) for
managing farms and greenhouses with varied crops. BYND Cannasoft
owns the patent-pending intellectual property for the EZ-G device.
This therapeutic device uses proprietary software to regulate the
flow of low concentrations of CBD oil, hemp seed oil, and other
natural oils into the soft tissues of the female reproductive
system to potentially treat a wide variety of women's health
issues. The EZ-G device includes technological advancements as a
sex toy with a more realistic experience and the prototype utilizes
sensors to determine what enhances the users' pleasure. The user
can control the device through a Bluetooth app installed on a
smartphone or other portable device. The data will be transmitted
and received from the device to and from the secure cloud using
artificial intelligence (AI). The data is combined with other
antonymic user preferences to improve its operation by increasing
sexual satisfaction.
For Further Information please refer to
information available on the Company’s website:
www.cannasoft-crm.com, the CSE’s website:
www.thecse.com/en/listings/life-sciences/bynd-cannasoft-enterprises-inc
and on SEDAR: www.sedar.com.
Gabi Kabazo
Chief Financial Officer
Tel: (604) 833-6820
e‐mail: ir@cannasoft-crm.com
For Media and Investor Relations, please
contact:
David L. Kugelman
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
dk@atlcp.com
Skype: kugsusa
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
involving risks and uncertainties, which may cause results to
differ materially from the statements made. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. When used in this
document, the words "may," "would," "could," "will," "intend,"
"plan," "anticipate," "believe," "estimate," "expect," "potential,"
"continue," "strategy," "future," "project," "target," and similar
expressions are intended to identify forward-looking statements,
though not all forward looking statements use these words or
expressions. All statements contained in this press release other
than statements of historical fact, including, without limitation,
statements regarding changes to our leadership team, our Cannabis
CRM platform, our expanded EZ-G patent application, the expected
benefits of our double-faceted condom design to users, our market
growth, and our objectives for future operations, are forward
looking statements. Additional regulatory standards may be
required, including FDA approval or any other approval for the
purpose of manufacturing, marketing, and selling the device under
therapeutic indications. There is no certainty that the
aforementioned approvals will be received, and all the information
in this release is forward-looking. Such statements reflect the
company's current views with respect to future events and are
subject to such risks and uncertainties. Many factors could cause
actual results to differ materially from the statements made,
including unanticipated regulatory requests and delays, final
patents approval, and those factors discussed in filings made by
the company with the Canadian securities regulatory authorities,
including (without limitation) in the company's management's
discussion and analysis for the nine month period ended September
30, 2022 and annual information form dated October 8, 2022, which
are available under the company's profile at www.sedar.com,
and in filings made with the U.S. Securities and Exchange
Commission. Should one or more of these factors occur, or should
assumptions underlying the forward-looking statements prove
incorrect, actual results may vary materially from those described
herein as intended, planned, anticipated, or expected. We do not
intend and do not assume any obligation to update these
forward‐looking statements, except as required by law. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change. Shareholders are cautioned not to put undue reliance on
such forward‐looking statements.
Femto Technologies (NASDAQ:BCAN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Femto Technologies (NASDAQ:BCAN)
Historical Stock Chart
From Dec 2023 to Dec 2024